For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...

Return to shareholders -- $1.4 billion was returned to shareholders as of fiscal Q3 2025 through dividends and share repurchases. Anticipated step-up in expenses -- Research and development, as well ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...

"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.

UN World Children's Day on Nov 20 is an annual reminder that every child deserves the chance not just to survive, but to ...

Snoop Dogg has brought major attention to the cause, reinforcing the message that awareness and education still matter - ...

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...